


# The Smarter Way to Forecast Pharma Markets

Empower your team with intuitive, best-practice forecasting tools designed for pharmaceutical success.



# Elevate Your Pharmaceutical Forecasting With FC+

A suite of advanced forecasting software that redefines industry standards.

Generate more accurate and actionable insights for any market, disease area, or product. By combining best practice methodologies, advanced analytics, and intuitive design, FC+ streamlines your forecasting process and supports confident decision-making.

CREATE AND POPULATE FORECASTING MODELS ANYTIME, ANYWHERE – EFFICIENTLY AND COST-EFFECTIVELY.

## Why Choose FC+

- >Create multiple forecasts efficiently
- Sophisticated inbuilt features and functionality
- Training and support included
- Consistent and transparent models
- Built on best practice forecasting principles
- Easy to use for all teams

	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z	
15		2015	2016	2017	2018	2019	2020	2021	2022	2023	2024															
16		321,418,821	323,137,500	325,511,000	327,892,000	330,269,000	332,639,000	334,009,000	335,379,000	336,749,000	338,119,000															
17	EUS total population	50.8 %	49.2 %	49.2 %	49.2 %	49.2 %	49.3 %	49.3 %	49.3 %	49.3 %	49.3 %															
18	Female %	50.8 %	49.2 %	49.2 %	49.2 %	49.2 %	49.3 %	49.3 %	49.3 %	49.3 %	49.3 %															
19	Female population	163,250,987	159,080,591	160,249,065	161,421,232	162,591,429	163,891,235	165,181,042	166,481,849	167,781,656	169,081,463															
20	Stage IV Incident Patients	9,672	9,807	9,943	10,079	10,215	10,350	10,451	10,552	10,653	10,754															
21	IBC Relapse Patients	54,026	54,685	55,344	56,002	56,661	57,320	57,813	58,307	58,801	59,295															
22	Stage IV Incidence / Relapse Pts	63,698	64,492	65,287	66,081	66,876	67,670	68,264	68,859	69,454	70,049															
23	Stage IV Diagnosis rate	95.0 %	95.0 %	95.0 %	95.0 %	95.0 %	95.0 %	95.0 %	95.0 %	95.0 %	95.0 %															
24	Diagnosed patients	60,513	61,267	62,022	62,777	63,532	64,136	64,851	65,416	65,981	66,546															
25	Stage IV Treatment Rate	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %															
26	Treated patients	60,513	61,267	62,022	62,777	63,532	64,136	64,851	65,416	65,981	66,546															
27																										
28																										
29																										
30																										
31																										
32	BRCA1 tested	60 %	60 %	60 %	60 %	60 %	60 %	60 %	60 %	60 %	60 %															
33	BRCA1 not tested	40 %	40 %	40 %	40 %	40 %	40 %	40 %	40 %	40 %	40 %															
34		100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %	100.0 %															
35																										
36																										
37																										
38																										
39	BRCA1 tested	38,219	38,695	39,172	39,649	40,125	40,602	40,959	41,316	41,672	42,029															
40	BRCA1 not tested	25,479	25,797	26,115	26,432	26,750	27,068	27,306	27,544	27,782	28,020															
41	Total Segments	63,698	64,492	65,287	66,081	66,876	67,670	68,264	68,859	69,454	70,049															
42																										
43																										

FC+

info@evaluate.com

Evaluate    
a norstella company  
an Evaluate company

www.evaluate.com

# A Suite of Pharma-Specific Modules

FC+ contains a suite of modules based on best practice principles to meet all your needs – from trend-based sales forecasts to complex patient flow models.

## EPI+

Epidemiology-based forecasting

## SALES+

Time series methodology for reliable sales forecasting

## ONCO+

Patient flow tailored towards oncology forecasting

## FLOW+

Patient flow for progressive diseases

All add-ins feature advanced capabilities like Monte Carlo simulation and SimScore market peak share estimation.

**EXCEL ADD-INS FOR PHARMACEUTICAL FORECASTING,  
BUILT ON DECADES OF INDUSTRY EXPERTISE.**

## Intuitive, Agile, Engaging, Innovative



Responsive and user-friendly Excel-based application



Modular approach: add to existing models or build from scratch



Visualize data in a click



Risk analysis, peak share predictor, demand analysis



Efficient, cost-effective, and flexible

“I love how simple FC+ is to follow.”

“FC+ is an exciting tool for quickly developing custom sales models.”

GLOBAL FORECASTING & COMMERCIAL ANALYTICS LEADERS

**FC+**

**Evaluate**    
a norstella company

FC+ has advanced capabilities to transform complex data into actionable insights, enabling teams to forecast with greater accuracy and confidence.



### SIMSCORE

Estimate peak share for new products



### P&L

Risk-adjusted KPIs (NPV, IRR, payback)



### CONSOLIDATION

Multi-country scenario consolidation



### DATA PHASER

Granular insights from annual to monthly data



### LICENSE REMOVER

Share models without extra licenses




### DEMAND ANALYSIS

Adjust for supply chain factors


Built on best practice forecasting principles, FC+ leverages proven methodologies and advanced analytics to ensure every forecast is clear, reliable, and tailored for success.

#### STEP 1 Define the market




Establish the size of the current market in the most appropriate manner for the specific forecast.

#### STEP 2 Trend the market



Trend out historical data to predict the future market and create a baseline forecast.

#### STEP 3 Add events



Account for future market changes that you can't predict from historical data, e.g. new products.

#### STEP 4 Convert to volume/sales

**FC+ ENSURES CLARITY, TRANSPARENCY, AND CONFIDENCE IN EVERY FORECAST.**

Ready to transform your pharmaceutical forecasting?  
Get in touch to find out how we can help.

[info@evaluate.com](mailto:info@evaluate.com) | [www.evaluate.com](http://www.evaluate.com)

Evaluate HQ: +44-(0)20-7377-0800 | Evaluate Americas: +1-617-573-9450 | Evaluate APAC: +81-(0)80-1164-4754

**Evaluate**   
a norstella company

an Evaluate company